Base de datos : MEDLINE
Búsqueda : estreptomicina [Palabras]
Referencias encontradas : 10525 [refinar]
Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 1053 va a la página                         

  1 / 10525 MEDLINE  
              next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28470446
[Au] Autor:Sundaran PS; Bhaskaran A; Alex ST; Prasad T; Haritha VH; Anie Y; Kumary TV; Anil Kumar PR
[Ad] Dirección:Division of Tissue Culture, Department of Applied Biology, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, 695 012, India.
[Ti] Título:Drug loaded microbeads entrapped electrospun mat for wound dressing application.
[So] Fuente:J Mater Sci Mater Med;28(6):88, 2017 Jun.
[Is] ISSN:1573-4838
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:A new design of antibiotic loaded wound dressing and its initial in vitro evaluation is described. Chitosan microbeads loaded with ampicillin were sandwiched within polycaprolactone electrospun mat (MbAPPCL). The morphology was analyzed by scanning electron microscopy and surface chemistry was characterized by Fourier Transform Infrared Spectroscopy. In vitro cytotoxicity using L-929 fibroblast cells by direct contact test and elution assay revealed non-cytotoxic nature of MbAPPCL. The cell adhesion and viability analysis further confirmed the cytocompatibility of MbAPPCL as a wound dressing material. Percentage hemolysis and platelet adhesion on the mat exposed to blood substantiated the hemocompatibility. The antibiotic susceptibility test analyzed on Staphylococcus aureus by agar plate method confirmed the drug release and antimicrobial property. The proposed wound dressing model explained with ampicillin as a candidate drug has the potential to include microbeads with different antibiotics for multi drug treatment.
[Mh] Términos MeSH primario: Vendajes
Portadores de Fármacos
Microesferas
[Mh] Términos MeSH secundario: Animales
Antibacterianos/química
Antibacterianos/farmacología
Materiales Biocompatibles
Plaquetas
Línea Celular
Quitosano
Técnicas Electroquímicas
Fibroblastos/fisiología
Ensayo de Materiales
Ratones
Penicilinas/química
Penicilinas/farmacología
Staphylococcus aureus/efectos de los fármacos
Estreptomicina/química
Estreptomicina/farmacología
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Anti-Bacterial Agents); 0 (Biocompatible Materials); 0 (Drug Carriers); 0 (Penicillins); 9012-76-4 (Chitosan); Y45QSO73OB (Streptomycin)
[Em] Mes de ingreso:1803
[Cu] Fecha actualización por clase:180309
[Lr] Fecha última revisión:180309
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170505
[St] Status:MEDLINE
[do] DOI:10.1007/s10856-017-5893-8


  2 / 10525 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
[PMID]:27776591
[Au] Autor:Lopez AL; Aldaba JG; Ama CG; Sylim PG; Geraldino XD; Sarol JN; Salonga AM
[Ad] Dirección:National Institutes of Health, University of the Philippines Manila, Manila, The Philippines.
[Ti] Título:Surveillance for tuberculosis in a rural community in The Philippines.
[So] Fuente:Int J Tuberc Lung Dis;20(11):1495-1500, 2016 Nov.
[Is] ISSN:1815-7920
[Cp] País de publicación:France
[La] Idioma:eng
[Ab] Resumen:SETTING: Estimates of the tuberculosis (TB) burden in the Philippines are largely dependent on prevalence surveys. OBJECTIVE: To conduct a prospective community-based survey to generate epidemiological data on TB among patients seeking care in public health centres in a rural municipality in the Philippines. DESIGN: Prospective surveillance and follow-up of presumptive TB cases from May 2013 to July 2015. RESULTS: Of 1622 participants with presumptive TB, 468 (28.8%) (95%CI 26.6-31.1) were diagnosed with TB. The annual TB case notification rate in San Juan was 212 (95%CI 184-242) per 100 000 population. There were nine TB-attributable deaths during the study period. Only 8.8% (95%CI 6.2-11.32) of the cases were children aged <15 years; 274 (58.5%) cases were bacteriologically confirmed. Of 210 isolates tested for antimicrobial resistance, 49 (23.3%, 95%CI 17.58-29.02) were resistant. Resistance to isoniazid (INH) was common (n = 33, 15.7%); multidrug-resistant TB was 1.9%. CONCLUSION: TB remains an important health problem in the Philippines. We identified low case detection of TB in children and high INH resistance rates in this rural community.
[Mh] Términos MeSH primario: Vigilancia de la Población
Población Rural
Tuberculosis Resistente a Múltiples Medicamentos/epidemiología
Tuberculosis/epidemiología
[Mh] Términos MeSH secundario: Adolescente
Adulto
Anciano
Antituberculosos/uso terapéutico
Niño
Preescolar
Femenino
Estudios de Seguimiento
Seres Humanos
Lactante
Recién Nacido
Isoniazida/uso terapéutico
Kanamicina/uso terapéutico
Masculino
Mediana Edad
Filipinas/epidemiología
Prevalencia
Estudios Prospectivos
Salud Pública
Rifampin/uso terapéutico
Estreptomicina/uso terapéutico
Resultado del Tratamiento
Tuberculosis/diagnóstico
Tuberculosis/tratamiento farmacológico
Tuberculosis Resistente a Múltiples Medicamentos/diagnóstico
Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico
Adulto Joven
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Antitubercular Agents); 59-01-8 (Kanamycin); V83O1VOZ8L (Isoniazid); VJT6J7R4TR (Rifampin); Y45QSO73OB (Streptomycin)
[Em] Mes de ingreso:1802
[Cu] Fecha actualización por clase:180214
[Lr] Fecha última revisión:180214
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:161026
[St] Status:MEDLINE


  3 / 10525 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28951283
[Au] Autor:Wälti MA; Clore GM
[Ad] Dirección:Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0520, United States.
[Ti] Título:Disassembly/reassembly strategy for the production of highly pure GroEL, a tetradecameric supramolecular machine, suitable for quantitative NMR, EPR and mutational studies.
[So] Fuente:Protein Expr Purif;142:8-15, 2018 Feb.
[Is] ISSN:1096-0279
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:GroEL, a prototypical member of the chaperonin class of chaperones, is a large supramocular machine that assists protein folding and plays an important role in proteostasis. GroEL comprises two heptameric rings, each of which encloses a large cavity that provides a folding chamber for protein substrates. Many questions remain regarding the mechanistic details of GroEL facilitated protein folding. Thus, data at atomic resolution of the type provided by NMR and EPR are invaluable. Such studies often require complete deuteration of GroEL, uniform or residue specific C and N isotope labeling, and the introduction of selective cysteine mutations for site-specific spin labeling. In addition, high purity GroEL is essential for detailed studies of substrate-GroEL interactions as quantitative interpretation is impossible if the cavities are already occupied and blocked by other protein substrates present in the bacterial expression system. Here we present a new purification protocol designed to provide highly pure GroEL devoid of non-specific protein substrate contamination.
[Mh] Términos MeSH primario: Chaperonina 60/aislamiento & purificación
Cromatografía en Gel/métodos
Cromatografía por Intercambio Iónico/métodos
Proteínas de Escherichia coli/aislamiento & purificación
Mutación Puntual
[Mh] Términos MeSH secundario: Sulfato de Amonio/química
Chaperonina 60/química
Chaperonina 60/genética
Chaperonina 60/metabolismo
Escherichia coli/genética
Escherichia coli/metabolismo
Proteínas de Escherichia coli/química
Proteínas de Escherichia coli/genética
Proteínas de Escherichia coli/metabolismo
Expresión Génica
Isótopos de Nitrógeno/química
Resonancia Magnética Nuclear Biomolecular
Multimerización de Proteína
Proteínas Recombinantes/química
Proteínas Recombinantes/genética
Proteínas Recombinantes/aislamiento & purificación
Proteínas Recombinantes/metabolismo
Estreptomicina/química
Urea/química
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Chaperonin 60); 0 (Escherichia coli Proteins); 0 (Nitrogen Isotopes); 0 (Recombinant Proteins); 8W8T17847W (Urea); SU46BAM238 (Ammonium Sulfate); Y45QSO73OB (Streptomycin)
[Em] Mes de ingreso:1711
[Cu] Fecha actualización por clase:171128
[Lr] Fecha última revisión:171128
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170928
[St] Status:MEDLINE


  4 / 10525 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28847258
[Au] Autor:López-Santamaría Donoso J; Viguera Guerra I
[Ad] Dirección:Hospital Universitario Reina Sofía, Córdoba. julia_lopez_2@hotmail.com.
[Ti] Título:[Formulation of neomycin and streptomycin for the digestive decontamination of carbapenemases producing klebsiella pneumoniae].
[Ti] Título:Nueva formulación de neomicina y estreptomicina para la descontaminación digestiva de klebsiella pneumoniae productora de carbapenemasas..
[So] Fuente:Farm Hosp;41(5):646, 2017 Sep 01.
[Is] ISSN:0214-753X
[Cp] País de publicación:Spain
[La] Idioma:spa
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1708
[Cu] Fecha actualización por clase:171114
[Lr] Fecha última revisión:171114
[St] Status:In-Process
[do] DOI:10.7399/fh.10749


  5 / 10525 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28841532
[Au] Autor:Zhang X; Qi S; Liu C; Zhao X
[Ad] Dirección:Department of Applied Chemistry, School of Science, Northwestern Polytechnical University, Xi'an 710129, China; Department of Pharmacy, Xi'an Medical University, Xi'an 710021, China.
[Ti] Título:Enantiomeric separation of five acidic drugs via capillary electrophoresis using streptomycin as chiral selector.
[So] Fuente:J Chromatogr B Analyt Technol Biomed Life Sci;1063:31-35, 2017 Sep 15.
[Is] ISSN:1873-376X
[Cp] País de publicación:Netherlands
[La] Idioma:eng
[Ab] Resumen:A simple capillary zone electrophoresis (CZE) method was developed to achieve the rapid enantiomeric separation of a set of acidic drugs using streptomycin as chiral selector. The enantiomers of 5 chiral phenyl-containing acidic pharmaceutical compounds were separated excellently by CE using an uncoated silica capillary. Several experimental parameters such as the concentration of streptomycin, buffer concentration and pH, running voltage, and capillary temperature were all investigated systematically in order to optimize the chiral separation. All analytes were got baseline separation within 10min. And the results showed that streptomycin can be used as a chiral selector to the enantioseparation of five acidic drugs by CZE method.
[Mh] Términos MeSH primario: Electroforesis Capilar/métodos
Preparaciones Farmacéuticas/aislamiento & purificación
Estreptomicina/química
[Mh] Términos MeSH secundario: Concentración de Iones de Hidrógeno
Preparaciones Farmacéuticas/análisis
Preparaciones Farmacéuticas/química
Estereoisomerismo
Temperatura Ambiental
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Pharmaceutical Preparations); Y45QSO73OB (Streptomycin)
[Em] Mes de ingreso:1710
[Cu] Fecha actualización por clase:171002
[Lr] Fecha última revisión:171002
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170826
[St] Status:MEDLINE


  6 / 10525 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28808159
[Au] Autor:Machelart A; Khadrawi A; Demars A; Willemart K; De Trez C; Letesson JJ; Muraille E
[Ad] Dirección:Unité de Recherche en Biologie des Microorganismes, Laboratoire d'Immunologie et de Microbiologie, Université de Namur, Namur, Belgium.
[Ti] Título:Chronic Brucella Infection Induces Selective and Persistent Interferon Gamma-Dependent Alterations of Marginal Zone Macrophages in the Spleen.
[So] Fuente:Infect Immun;85(11), 2017 Nov.
[Is] ISSN:1098-5522
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:The spleen is known as an important filter for blood-borne pathogens that are trapped by specialized macrophages in the marginal zone (MZ): the CD209 MZ macrophages (MZMs) and the CD169 marginal metallophilic macrophages (MMMs). Acute systemic infection strongly impacts MZ populations and the location of T and B lymphocytes. This phenomenon has been linked to reduced chemokine secretion by stromal cells. spp. are the causative agent of brucellosis, a widespread zoonotic disease. Here, we used infection as a model to investigate the impact of chronic stealth infection on splenic MZ macrophage populations. During the late phase of infection, we observed a loss of both MZMs and MMMs, with a durable disappearance of MZMs, leading to a reduction of the ability of the spleen to take up soluble antigens, beads, and unrelated bacteria. This effect appears to be selective as every other lymphoid and myeloid population analyzed increased during infection, which was also observed following and infection. Comparison of wild-type and deficient mice suggested that MZ macrophage population loss is dependent on interferon gamma (IFN-γ) receptor but independent of T cells or tumor necrosis factor alpha receptor 1 (TNF-αR1) signaling pathways and is not correlated to an alteration of CCL19, CCL21, and CXCL13 chemokine mRNA expression. Our results suggest that MZ macrophage populations are particularly sensitive to persistent low-level IFN-γ-mediated inflammation and that infection could reduce the ability of the spleen to perform certain MZM- and MMM-dependent tasks, such as antigen delivery to lymphocytes and control of systemic infection.
[Mh] Términos MeSH primario: Brucelosis/inmunología
Interacciones Huésped-Patógeno
Interferón gamma/inmunología
Macrófagos/inmunología
Receptores de Interferón/inmunología
Bazo/inmunología
[Mh] Términos MeSH secundario: Animales
Antibacterianos/farmacología
Linfocitos B/inmunología
Linfocitos B/microbiología
Brucella abortus/efectos de los fármacos
Brucella abortus/inmunología
Brucella abortus/patogenicidad
Brucella melitensis/efectos de los fármacos
Brucella melitensis/inmunología
Brucella melitensis/patogenicidad
Brucella suis/efectos de los fármacos
Brucella suis/inmunología
Brucella suis/patogenicidad
Brucelosis/tratamiento farmacológico
Brucelosis/genética
Brucelosis/microbiología
Quimiocina CCL19/genética
Quimiocina CCL19/inmunología
Quimiocina CCL21/genética
Quimiocina CCL21/inmunología
Quimiocina CXCL13/genética
Quimiocina CXCL13/inmunología
Enfermedad Crónica
Regulación de la Expresión Génica
Interferón gamma/genética
Macrófagos/microbiología
Ratones
Ratones Consanguíneos C57BL
Ratones Noqueados
ARN Mensajero/genética
ARN Mensajero/inmunología
Receptores de Interferón/deficiencia
Receptores de Interferón/genética
Receptores Tipo I de Factores de Necrosis Tumoral/deficiencia
Receptores Tipo I de Factores de Necrosis Tumoral/genética
Receptores Tipo I de Factores de Necrosis Tumoral/inmunología
Rifampin/farmacología
Transducción de Señales
Bazo/microbiología
Estreptomicina/farmacología
Linfocitos T/inmunología
Linfocitos T/microbiología
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Anti-Bacterial Agents); 0 (Ccl19 protein, mouse); 0 (Chemokine CCL19); 0 (Chemokine CCL21); 0 (Chemokine CXCL13); 0 (Cxcl13 protein, mouse); 0 (RNA, Messenger); 0 (Receptors, Interferon); 0 (Receptors, Tumor Necrosis Factor, Type I); 0 (interferon gamma receptor); 82115-62-6 (Interferon-gamma); VJT6J7R4TR (Rifampin); Y45QSO73OB (Streptomycin)
[Em] Mes de ingreso:1710
[Cu] Fecha actualización por clase:171024
[Lr] Fecha última revisión:171024
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170816
[St] Status:MEDLINE


  7 / 10525 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28757138
[Au] Autor:Mehta H; Goulet PO; Mashiko S; Desjardins J; Pérez G; Koenig M; Senécal JL; Constante M; Santos MM; Sarfati M
[Ad] Dirección:Immunoregulation Laboratory, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada.
[Ti] Título:Early-Life Antibiotic Exposure Causes Intestinal Dysbiosis and Exacerbates Skin and Lung Pathology in Experimental Systemic Sclerosis.
[So] Fuente:J Invest Dermatol;137(11):2316-2325, 2017 Nov.
[Is] ISSN:1523-1747
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:Patients with systemic sclerosis (SSc) display altered intestinal microbiota. However, the influence of intestinal dysbiosis on the development of experimental SSc remains unknown. Topoisomerase I peptide-loaded dendritic cell immunization induces SSc-like disease, with progressive skin and lung fibrosis. Breeders were given streptomycin and pups continued to receive antibiotic (ATB) until endpoint (lifelongATB). Alternately, ATB was withdrawn (earlyATB) or initiated (adultATB) during adulthood. Topoisomerase I peptide-loaded dendritic cell (no ATB) immunization induced pronounced skin fibrosis, with increased matrix (Col1a1), profibrotic (Il13, Tweakr), and vascular function (Serpine1) gene expression. Remarkably, earlyATB exposure was sufficient to augment skin Col5a1 and Il13 expression, and inflammatory cell infiltration, which included IL-13 cells, mononuclear phagocytes, and mast cells. Moreover, skin pathology exacerbation was also observed in lifelongATB and adultATB groups. Oral streptomycin administration induced intestinal dysbiosis, with exposure limited to early life (earlyATB) being sufficient to cause long-term modification of the microbiota and a shift toward increased Bacteroidetes/Firmicutes ratio. Finally, aggravated lung fibrosis and dysregulated pulmonary T-cell responses were observed in earlyATB and lifelongATB but not adultATB-exposed mice. Collectively, intestinal microbiota manipulation with streptomycin exacerbated pathology in two distinct sites, skin and lungs, with early life being a critical window to affect the course of SSc-like disease.
[Mh] Términos MeSH primario: Disbiosis/genética
Microbioma Gastrointestinal/efectos de los fármacos
Fibrosis Pulmonar/patología
Esclerodermia Sistémica/genética
Esclerodermia Sistémica/inmunología
Estreptomicina/farmacología
[Mh] Términos MeSH secundario: Factores de Edad
Animales
Células Cultivadas
ADN Bacteriano/análisis
Células Dendríticas/efectos de los fármacos
Modelos Animales de Enfermedad
Disbiosis/microbiología
Femenino
Microbioma Gastrointestinal/genética
Seres Humanos
Masculino
Ratones
Ratones Consanguíneos BALB C
Ratones Transgénicos
Fibrosis Pulmonar/genética
Distribución Aleatoria
Reacción en Cadena en Tiempo Real de la Polimerasa/métodos
Factores de Riesgo
Esclerodermia Sistémica/patología
Estadísticas no Paramétricas
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (DNA, Bacterial); Y45QSO73OB (Streptomycin)
[Em] Mes de ingreso:1711
[Cu] Fecha actualización por clase:171102
[Lr] Fecha última revisión:171102
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170801
[St] Status:MEDLINE


  8 / 10525 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28628661
[Au] Autor:Wang Y; Li J; Xiong K; Chen Z; Zheng C; Tan Y; Cong Y
[Ad] Dirección:Department of Microbiology, Third Military Medical University, Chongqing, China.
[Ti] Título:Elimination of persistent vaccine bacteria of Salmonella enterica serovar Typhimurium in the guts of immunized mice by inducible expression of truncated YncE.
[So] Fuente:PLoS One;12(6):e0179649, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:Orally administered vaccine bacteria usually persist for a period of time in the intestinal tracts of immunized individuals, and are excreted in feces to the environment resulting in a potential biosafety issue. The releasing risk can be minimized by immediate elimination of the persistent vaccine bacteria once adequate protective immune responses have been elicited by the vaccine bacteria. In a previous study, inducible expression of truncated yncE gene (yncE*) was found lethal to host bacteria. This feature has an application potential in biosafety control. Here, we assessed the efficacy of YncE* in eliminating an attenuated strain of Salmonella enterica serovar Typhimurium in a mouse model. To this end, a pBAD-derived plasmid containing yncE* under the control of the Ara promoter was transformed into a ΔphoPQ mutant of S. Typhimurium. Our data show that the induced expression of yncE* in the presence of arabinose eliminated the vaccine bacteria both in vitro and in vivo. BALB/c mice with or without streptomycin-pretreatment were used to assess the efficacy of YncE* in vivo. Oral administration of 500 µl of 20% arabinose at 24 h postvaccination removed the vaccine bacteria from the guts of the tested mice without streptomycin-pretreatment. For streptomycin-pretreated mice, which were colonized with higher levels of Salmonella, an additional gavage of arabinose was required to completely eliminate the vaccine bacteria in the guts of the tested mice. The orally administered arabinose did not affect the persistence of bacteria that had penetrated the intestinal mucosa of the immunized mice. Furthermore, there was no significant difference in the protection rate between the routine immunization and the immunization with the arabinose treatment. The results indicate that the yncE* element improves the biosafety of the bacterial vaccine, and can be taken in consideration in future design of live bacterial vaccines.
[Mh] Términos MeSH primario: Proteínas Bacterianas/metabolismo
Infecciones por Salmonella/prevención & control
Vacunas contra la Salmonella/inmunología
Salmonella typhimurium/metabolismo
Vacunas Atenuadas/inmunología
[Mh] Términos MeSH secundario: Animales
Anticuerpos Antibacterianos/sangre
Arabinosa/farmacología
Proteínas Bacterianas/genética
Modelos Animales de Enfermedad
Femenino
Expresión Génica/efectos de los fármacos
Intestinos/microbiología
Dosificación Letal Mediana
Lipopolisacáridos/inmunología
Ratones
Ratones Consanguíneos BALB C
Plásmidos/genética
Plásmidos/metabolismo
Infecciones por Salmonella/microbiología
Salmonella typhimurium/efectos de los fármacos
Estreptomicina/farmacología
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Antibodies, Bacterial); 0 (Bacterial Proteins); 0 (Lipopolysaccharides); 0 (PhoQ protein, Bacteria); 0 (Salmonella Vaccines); 0 (Vaccines, Attenuated); 125360-99-8 (PhoP protein, Bacteria); B40ROO395Z (Arabinose); Y45QSO73OB (Streptomycin)
[Em] Mes de ingreso:1709
[Cu] Fecha actualización por clase:170921
[Lr] Fecha última revisión:170921
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170620
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0179649


  9 / 10525 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo SciELO Brasil
Texto completo SciELO Salud Pública
[PMID]:28489185
[Au] Autor:Fregona G; Cosme LB; Moreira CMM; Bussular JL; Dettoni VDV; Dalcolmo MP; Zandonade E; Maciel ELN
[Ad] Dirección:Programa de Pós-Graduação em Saúde Coletiva. Hospital Universitário Cassiano Antônio de Moraes. Universidade Federal do Espírito Santo. Vitória, ES, Brasil.
[Ti] Título:Risk factors associated with multidrug-resistant tuberculosis in Espírito Santo, Brazil.
[So] Fuente:Rev Saude Publica;51(0):41, 2017 Apr 27.
[Is] ISSN:1518-8787
[Cp] País de publicación:Brazil
[La] Idioma:eng; por
[Ab] Resumen:OBJECTIVE: To analyze the prevalence and factors associated with multidrug-resistant tuberculosis in Espírito Santo, Brazil. METHODS: This is a cross-sectional study of cases of tuberculosis tested for first-line drugs (isoniazid, rifampicin, pyrazinamide, ethambutol, and streptomycin) in Espírito Santo between 2002 and 2012. We have used laboratory data and registration of cases of tuberculosis - from the Sistema Nacional de Agravos de Notificação and Sistema para Tratamentos Especiais de Tuberculose. Individuals have been classified as resistant and non-resistant and compared in relation to the sociodemographic, clinical, and epidemiological variables. Some variables have been included in a logistic regression model to establish the factors associated with resistance. RESULTS: In the study period, 1,669 individuals underwent anti-tuberculosis drug susceptibility testing. Of these individuals, 10.6% showed resistance to any anti-tuberculosis drug. The rate of multidrug resistance observed, that is, to rifampicin and isoniazid, has been 5%. After multiple analysis, we have identified as independent factors associated with resistant tuberculosis: history of previous treatment of tuberculosis [recurrence (OR = 7.72; 95%CI 4.24-14.05) and re-entry after abandonment (OR = 3.91; 95%CI 1.81-8.43)], smoking (OR = 3.93; 95%CI 1.98-7.79), and positive culture for Mycobacterium tuberculosis at the time of notification of the case (OR = 3.22; 95%CI 1.15-8.99). CONCLUSIONS: The partnership between tuberculosis control programs and health teams working in the network of Primary Health Care needs to be strengthened. This would allow the identification and monitoring of individuals with a history of previous treatment of tuberculosis and smoking. Moreover, the expansion of the offer of the culture of tuberculosis and anti-tuberculosis drug susceptibility testing would provide greater diagnostic capacity for the resistant types in Espírito Santo. OBJETIVO: Analisar a prevalência e fatores associados à tuberculose resistente no Espírito Santo. MÉTODOS: Estudo transversal dos casos de tuberculose testados para fármacos de primeira linha (isoniazida, rifampicina, pirazinamida, etambutol e estreptomicina) no Espírito Santo entre 2002 e 2012. Foram utilizados dados laboratoriais e de registro de casos de tuberculose - Sistema Nacional de Agravos de Notificação e Sistema para Tratamentos Especiais de Tuberculose. Os indivíduos foram classificados em resistentes e não resistentes, e comparados para variáveis sociodemográficas, clínicas e epidemiológicas. Algumas variáveis foram inclusas em um modelo de regressão logística para estabelecimento de fatores associados à resistência. RESULTADOS: No período do estudo, 1.669 indivíduos tiveram o teste de sensibilidade aos fármacos antituberculose realizado. Destes, 10,6% apresentaram resistência a qualquer droga antituberculose. A taxa de multirresistência observada, isto é, à rifampicina e isoniazida, foi de 5%. Após a análise múltipla, foram identificados como fatores associados independentes para tuberculose resistente: história de tratamento prévio para tuberculose [Recidiva (OR = 7,72; IC95% 4,24-14,05) e reingresso após abandono (OR = 3,91; IC95% 1,81-8,43)], tabagismo (OR = 3,93; IC95% 1,98-7,79) e cultura positiva para Mycobacterium tuberculosis no momento da notificação do caso (OR = 3,22; IC95% 1,15-8,99). CONCLUSÕES: É necessário o fortalecimento da parceria entre os programas de controle de tuberculose e as equipes de saúde que atuam na rede de Atenção Primária à Saúde. Isso possibilitaria identificar e acompanhar indivíduos com história de tratamento prévio para tuberculose e tabagismo. Além disso, a ampliação da oferta de cultura e Teste de Sensibilidade a fármacos antituberculose proporcionaria maior capacidade diagnóstica para as formas resistentes no Espírito Santo.
[Mh] Términos MeSH primario: Tuberculosis Resistente a Múltiples Medicamentos/epidemiología
[Mh] Términos MeSH secundario: Adulto
Brasil/epidemiología
Estudios Transversales
Femenino
Seres Humanos
Masculino
Mediana Edad
Prevalencia
Factores de Riesgo
Factores Socioeconómicos
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1706
[Cu] Fecha actualización por clase:170629
[Lr] Fecha última revisión:170629
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170511
[St] Status:MEDLINE


  10 / 10525 MEDLINE  
              first record previous record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28419091
[Au] Autor:Moura de Sousa J; Balbontín R; Durão P; Gordo I
[Ad] Dirección:Instituto Gulbenkian de Ciência, Oeiras, Portugal.
[Ti] Título:Multidrug-resistant bacteria compensate for the epistasis between resistances.
[So] Fuente:PLoS Biol;15(4):e2001741, 2017 Apr.
[Is] ISSN:1545-7885
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:Mutations conferring resistance to antibiotics are typically costly in the absence of the drug, but bacteria can reduce this cost by acquiring compensatory mutations. Thus, the rate of acquisition of compensatory mutations and their effects are key for the maintenance and dissemination of antibiotic resistances. While compensation for single resistances has been extensively studied, compensatory evolution of multiresistant bacteria remains unexplored. Importantly, since resistance mutations often interact epistatically, compensation of multiresistant bacteria may significantly differ from that of single-resistant strains. We used experimental evolution, next-generation sequencing, in silico simulations, and genome editing to compare the compensatory process of a streptomycin and rifampicin double-resistant Escherichia coli with those of single-resistant clones. We demonstrate that low-fitness double-resistant bacteria compensate faster than single-resistant strains due to the acquisition of compensatory mutations with larger effects. Strikingly, we identified mutations that only compensate for double resistance, being neutral or deleterious in sensitive or single-resistant backgrounds. Moreover, we show that their beneficial effects strongly decrease or disappear in conditions where the epistatic interaction between resistance alleles is absent, demonstrating that these mutations compensate for the epistasis. In summary, our data indicate that epistatic interactions between antibiotic resistances, leading to large fitness costs, possibly open alternative paths for rapid compensatory evolution, thereby potentially stabilizing costly multiple resistances in bacterial populations.
[Mh] Términos MeSH primario: Farmacorresistencia Bacteriana/genética
Farmacorresistencia Bacteriana Múltiple/genética
Epistasis Genética
Escherichia coli/genética
Mutación
[Mh] Términos MeSH secundario: Alelos
Antibacterianos/farmacología
Secuencia de Bases
Evolución Molecular Dirigida
Escherichia coli/efectos de los fármacos
Proteínas de Escherichia coli/genética
Regulación Bacteriana de la Expresión Génica/efectos de los fármacos
Aptitud Genética/efectos de los fármacos
Pruebas de Sensibilidad Microbiana
Factores de Elongación de Péptidos/genética
Secuencias Reguladoras de Ácidos Nucleicos/genética
Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
Proteínas Ribosómicas/genética
Rifampin/farmacología
Estreptomicina/farmacología
Factores de Transcripción/genética
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Anti-Bacterial Agents); 0 (Escherichia coli Proteins); 0 (NusG protein, E coli); 0 (Peptide Elongation Factors); 0 (Ribosomal Proteins); 0 (Transcription Factors); 0 (ribosomal protein S10); VJT6J7R4TR (Rifampin); Y45QSO73OB (Streptomycin)
[Em] Mes de ingreso:1705
[Cu] Fecha actualización por clase:170522
[Lr] Fecha última revisión:170522
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170419
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pbio.2001741



página 1 de 1053 va a la página                         
   


Refinar la búsqueda
  Base de datos : MEDLINE Formulario avanzado   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud